Research programme: P2 receptor modulators - Inspire Pharmaceuticals
Alternative Names: INS 117284; INS 48506; INS 48821; INS 48824; Non-P2Y2 receptor modulators - Inspire; P2X3 receptor antagonists - Inspire; P2Y12 receptor antagonists - InspireLatest Information Update: 04 Nov 2017
At a glance
- Originator Inspire Pharmaceuticals
- Developer Inspire Pharmaceuticals; Merck & Co
- Class
- Mechanism of Action Purinergic P2 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain; Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA
- 16 May 2011 Inspire Pharmaceuticals has been acquired by Merck & Co
- 25 Mar 2009 Preclinical development is ongoing for Thrombosis